Safety and Efficacy Of Obinutuzumab (GA101) With Fludarabine/Cyclophosphamide (G-FC) Or Bendamustine (G-B) In The Initial Therapy Of Patients With Chronic Lymphocytic Leukemia (CLL): Results From The Phase 1b Galton Trial (GA04779g)

被引：6
|
作者：
Brown, Jennifer R.
O'Brien, Susan
Kingsley, C. Daniel
Eradat, Herbert
Pagel, John M.
Lymp, James
Hirata, Jamie
Kipps, Thomas J.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.523.523
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
523
引用
收藏
页数：1
相关论文
共 26 条
  • [1] Final results of the phase 1b GALTON trial in chronic lymphocytic leukemia: durable remissions with frontline obinutuzumab (G) plus fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B)
    Brown, Jennifer
    Kingsley, Clint Daniel
    Eradat, Herbert
    Tyson, Nicola
    Hirata, Jamie
    Kipps, Thomas J.
    O'Brien, Susan
    Pagel, John M.
    LEUKEMIA & LYMPHOMA, 2017, 58 : 168 - 169
  • [2] FINAL RESULTS OF THE PHASE IB GALTON TRIAL IN CHRONIC LYMPHOCYTIC LEUKEMIA: DURABLE REMISSIONS WITH FRONTLINE OBINUTUZUMAB (G) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE (G-FC) OR BENDAMUSTINE (G-B)
    Brown, J.
    O'Brien, S.
    Kinglsey, C. D.
    Eradat, H.
    Pagel, J. M.
    Vignal, C.
    Hirata, J.
    Kipps, T. J.
    HAEMATOLOGICA, 2017, 102 : 73 - 73
  • [3] Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial
    Brown, Jennifer R.
    O'Brien, Susan
    Kingsley, C. Daniel
    Eradat, Herbert
    Pagel, John M.
    Lymp, James
    Hirata, Jamie
    Kipps, Thomas J.
    BLOOD, 2015, 125 (18) : 2779 - 2785
  • [4] BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)
    Cramer, P.
    von Tresckow, J.
    Bahlo, J.
    Robrecht, S.
    Al Sawaf, O.
    Langerbeins, P.
    Engelke, A.
    Fink, A. -M.
    Fischer, K.
    Seiler, T.
    von Weikersthal, L. Fischer
    Hebart, H.
    Kreuzer, K. -A.
    Ritgen, M.
    Kneba, M.
    Wendtner, C. -M.
    Stilgenbauer, S.
    Eichhorst, B.
    Hallek, M.
    HAEMATOLOGICA, 2017, 102 : 171 - 172
  • [5] CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial
    von Tresckow, Julia
    Cramer, Paula
    Bahlo, Jasmin
    Robrecht, Sandra
    Engelke, Anja
    Langerbeins, Petra
    Fink, Anna-Maria
    Illmer, Thomas
    Klaproth, Holger
    Estenfelder, Sven
    Ritgen, Matthias
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Bottcher, Sebastian
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [6] CLL2-BIG - A Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients With Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 19 - 21
  • [7] Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial.
    Flynn, Joseph M.
    Byrd, John C.
    Kipps, Thomas J.
    Boxer, Michael
    Kolibaba, Kathryn S.
    Tyson, Nicola
    Hirata, Jamie H.
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial
    von Tresckow, Julia
    Cramer, Paula
    Bahlo, Jasmin
    Engelke, Anja
    Langerbeins, Petra
    Fink, Anna-Maria
    Klaproth, Holger
    Tausch, Eugen
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2015, 126 (23)
  • [9] CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial
    von Tresckow, J.
    Cramer, P.
    Bahlo, J.
    Engelke, A.
    Langerbeins, P.
    Fink, A. -M.
    Klaproth, H.
    Tausch, E.
    Fischer, K.
    Wendtner, C. -M.
    Kreuzer, K. -A.
    Stilgenbauer, S.
    Boettcher, S.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 117 - 118
  • [10] Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG)
    Cramer, P.
    von Tresckow, J.
    Bahlo, J.
    Robrecht, S.
    Al-Sawaf, O.
    Langerbeins, P.
    Engelke, A.
    Fink, A. -M.
    Fischer, K.
    Tausch, E.
    Seiler, T.
    von Weikersthal, Fischer L.
    Hebart, H.
    Kreuzer, K. -A.
    Ritgen, M.
    Kneba, M.
    Wendtner, C. -M.
    Stilgenbauer, S.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 24 - 24
123